^
    Apply
    S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00617708)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/08/2022
    Initiation :
    03/01/2008
    Primary completion :
    09/01/2012
    Completion :
    02/25/2014
    EGFR
    |
    erlotinib • gemcitabine • cixutumumab (IMC A12)
    Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer (NCT00684983)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/24/2020
    Initiation :
    07/30/2008
    Primary completion :
    01/07/2014
    Completion :
    10/15/2019
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)
    Preoperative Treatment With Cetuximab and/or IMC-A12 (NCT00957853)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    03/19/2020
    Initiation :
    10/17/2011
    Primary completion :
    08/15/2018
    Completion :
    08/15/2018
    EGFR
    |
    Erbitux (cetuximab) • cixutumumab (IMC A12)
    A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer (NCT00781911)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/20/2019
    Initiation :
    02/01/2009
    Primary completion :
    07/01/2011
    Completion :
    05/01/2016
    IGF1 • IGF2
    |
    cixutumumab (IMC A12) • octreotide acetate solution for injection
    A Study in Non-Small Cell Lung Cancer (NCT01232452)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/20/2019
    Initiation :
    04/01/2011
    Primary completion :
    01/01/2013
    Completion :
    06/01/2016
    IGF1 • IGFBP3
    |
    cisplatin • pemetrexed • cixutumumab (IMC A12)
    BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer (NCT01263782)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/15/2019
    Initiation :
    05/17/2011
    Primary completion :
    08/15/2017
    Completion :
    08/15/2017
    EGFR • ALK
    |
    EGFR mutation • ALK fusion
    |
    Avastin (bevacizumab) • carboplatin • pemetrexed • cixutumumab (IMC A12)
    Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/11/2018
    Initiation :
    06/18/2012
    Primary completion :
    04/01/2014
    Completion :
    04/01/2014
    mTOR • IR
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)
    A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer (NCT00728949)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    06/06/2018
    Initiation :
    08/01/2008
    Primary completion :
    03/01/2012
    Completion :
    02/01/2015
    ER • PGR
    |
    tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • cixutumumab (IMC A12)
    Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy (NCT00503685)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    06/06/2018
    Initiation :
    06/01/2007
    Primary completion :
    03/01/2009
    Completion :
    03/01/2009
    KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3
    |
    KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1
    |
    Erbitux (cetuximab) • cixutumumab (IMC A12)
    A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT01182883)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    07/02/2017
    Initiation :
    07/28/2010
    Primary completion :
    04/04/2012
    Completion :
    04/04/2012
    AFP
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)
    Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer (NCT00678769)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/04/2015
    Initiation :
    05/01/2008
    Primary completion :
    06/01/2013
    Completion :
    10/01/2015
    PTEN • AKT1 • KDR • IRS1
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)